State Development and Investment Corporation
Chinese drug developer RemeGen raises $100m
RemeGen, a Chinese drug developer, has raised a $100 million round led by Lilly Asia Ventures and Lake Bleu Capital.
Cancer drug developer Innovent Biologics files for HK IPO
Innovent Biologics, a Chinese drug developer company with a number of PE backers, has filed for an IPO in Hong Kong under recently introduced rules allowing listings by biotech companies with no revenue or profits.
Chinese biotech firm Biocytogen raises $65m
Biocytogen, a Chinese contract research organization (CRO) that provides genetically engineered mice for drug testing, has raised RMB410 million ($65 million) in a Series C round of funding led by CMB International Capital, an investment arm of China...
NSSF teams up with SDIC to boost asset value
China's National Council for Social Security Fund has signed a framework agreement with State Development and Investment Corporation (SDIC) to boost the value of the state pension fund and state-owned assets.